Current Affairs - Business - Discussion

Zydus Lifesciences has obtained in-principle approval from the World Health Organization (WHO) for its Typhoid Vi conjugate vaccine, ZyVac TCV. This approval allows the vaccine to be eligible for procurement by the United Nations, marking a significant achievement for the company. Manufactured at Zydus Biotech Park in Ahmedabad, ZyVac TCV is designed to provide protection against Salmonella typhi for individuals aged 6 months to 65 years. This development highlights Zydus Lifesciences' commitment to addressing public health challenges through innovative vaccine solutions.